Barker Jenny C, DiBartola Kaitlin, Wee Corinne, Andonian Nicole, Abdel-Rasoul Mahmoud, Lowery Deborah, Janis Jeffrey E
From the Departments of Plastic Surgery, Anesthesia, and Biomedical Informatics, Center for Biostatistics, The Ohio State University Medical Center.
Plast Reconstr Surg. 2018 Oct;142(4):443e-450e. doi: 10.1097/PRS.0000000000004804.
The opioid epidemic demands changes in perioperative pain management. Of the 33,000 deaths attributable to opioid overdose in 2015, half received prescription opioids. Multimodal analgesia is a practice-altering evolution that reduces reliance on opioid medications. Ambulatory breast surgery is an ideal opportunity to implement these strategies.
A retrospective review of 560 patients undergoing outpatient breast procedures was conducted. Patients received (1) no preoperative analgesia (n = 333); (2) intraoperative intravenous acetaminophen (n = 78); (3) preoperative oral acetaminophen and gabapentin (n = 95); or (4) preoperative oral acetaminophen, gabapentin and celecoxib (n = 54). Outcomes included postanesthesia care unit narcotic use, pain scores, postanesthesia care unit length of stay, rescue antiemetic use, and 30-day complications.
Both oral multimodal analgesia regimens significantly reduced postanesthesia care unit narcotic use (oral acetaminophen and gabapentin, 14.3 ± 1.7; oral gabapentin, acetaminophen, and celecoxib, 11.9 ± 2.2; versus no drug, 19.2 ± 1.1 mg oral morphine equivalents; p = 0.0006), initial pain scores (oral acetaminophen and gabapentin, 3.9 ± 0.4; oral gabapentin, acetaminophen, and celecoxib, 3.4 ± 0.7; versus no drug, 5.3 ± 0.3 on a 1 to 10 scale, p = 0.0002) and maximum pain scores (oral acetaminophen and gabapentin, 4.3 ± 0.4; oral gabapentin, acetaminophen, and celecoxib, 3.6 ± 0.7; versus no drug, 5.9 ± 0.3 on a 1 to 10 scale; p < 0.0001). Both oral regimens were better than no medications or intravenous acetaminophen alone in multivariate models after controlling for age, body mass index, American Society of Anesthesiologists class, length of surgery, prior narcotic prescription availability, and intraoperative local anesthetic. Postanesthesia care unit length of stay, antiemetic use, and 30-day complications were not different.
Preoperative oral multimodal analgesia reduces narcotic use and pain scores in outpatient breast plastic surgery. These regimens are inexpensive, improve pain control, and contribute to narcotic-sparing clinical practice in the setting of a national opioid epidemic.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
阿片类药物泛滥要求围手术期疼痛管理做出改变。2015年,在33000例因阿片类药物过量导致的死亡病例中,有一半曾接受过阿片类药物处方。多模式镇痛是一种改变实践的演变,可减少对阿片类药物的依赖。门诊乳腺手术是实施这些策略的理想契机。
对560例行门诊乳腺手术的患者进行回顾性研究。患者接受以下处理:(1)未进行术前镇痛(n = 333);(2)术中静脉注射对乙酰氨基酚(n = 78);(3)术前口服对乙酰氨基酚和加巴喷丁(n = 95);或(4)术前口服对乙酰氨基酚、加巴喷丁和塞来昔布(n = 54)。观察指标包括麻醉后恢复室的阿片类药物使用情况、疼痛评分、麻醉后恢复室住院时间、急救止吐药使用情况以及30天并发症。
两种口服多模式镇痛方案均显著减少了麻醉后恢复室的阿片类药物使用量(口服对乙酰氨基酚和加巴喷丁组,14.3±1.7;口服加巴喷丁、对乙酰氨基酚和塞来昔布组,11.9±2.2;未用药组,19.2±1.1毫克口服吗啡当量;p = 0.0006)、初始疼痛评分(口服对乙酰氨基酚和加巴喷丁组,3.9±0.4;口服加巴喷丁、对乙酰氨基酚和塞来昔布组,3.4±0.7;未用药组,1至10分制下为5.3±0.3,p = 0.0002)以及最大疼痛评分(口服对乙酰氨基酚和加巴喷丁组,4.3±0.4;口服加巴喷丁、对乙酰氨基酚和塞来昔布组,3.6±0.7;未用药组,1至10分制下为5.9±0.3;p < 0.0001)。在控制了年龄、体重指数、美国麻醉医师协会分级、手术时长、既往阿片类药物处方可用性以及术中局部麻醉药等因素的多变量模型中,两种口服方案均优于未用药或仅静脉注射对乙酰氨基酚。麻醉后恢复室住院时间、止吐药使用情况以及30天并发症无差异。
术前口服多模式镇痛可减少门诊乳腺整形手术中的阿片类药物使用和疼痛评分。这些方案成本低廉,可改善疼痛控制,并有助于在全国阿片类药物泛滥的背景下开展减少阿片类药物使用的临床实践。
临床问题/证据级别:治疗性,III级